NAARDEN, Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)--Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, today announced the presentation of the latest research from the pridopidine Huntington disease (HD) and amyotrophic lateral sclerosis (ALS) programs at the American Academy of Neurology (AAN) Annual Congress, in Denver, Colorado, April 13-18.
Pridopidine is now in pre-registration phase in HD, with a first submission planned Mid 2024i, and is also set to commence a global Phase 3 study in ALS later this year. We are making significant strides forward and this is reflected by presentation of the data at one of the most important medical congresses in the field of Neurology. Pridopidine is one of the most advanced investigational new drugs in HD and ALS and has shown consistent treatment benefits across independent measures that are important to patients and families. The presented data advances knowledge in the field, providing important learnings for both clinical practice and for the design of our programs going forward. This advance is evident with novel findings from studies showing benefit with pridopidine in those with HD who are not taking anti-dopaminergic medication (ADMs) and a positive impact on speech and prolonged survival with pridopidine treatment in ALS.
Jina Swarz, MD. Ph.D.
The recently appointed Chief Medical Officer of Prilenia
Two oral and one poster presentations will be made at AAN 2024:
Oral Presentations:
Analyses of the Phase 3 Trial of Pridopidine’s Outcome On Function in Huntington Disease (PROOF-HD) Demonstrates Efficacy in Participants Without Antidopaminergic Medication
Session name - S30: Movement Disorders: Clinical Trials in Movement Disorders; Program Number: S30.002. Presented by: Michael R Hayden, Founder and CEO, Prilenia Therapeutics; Wed, April 17, at 1:12 PM (MT)
Pridopidine for the Treatment of ALS – Results from the Phase 2 HEALEY ALS Platform Trial
Session name - S5: ALS and CMT: New Therapeutic Approaches; Program Number: S5.003. Presented by: Jeremy M Shefner, Professor, Department of Neurology, Barrow Neurological Institute; Sun, April 14, at 3:54 PM (MT)
Poster Presentation:
Analyses of the Phase 3 Trial of Pridopidine’s Outcome On Function in Huntington Disease (PROOF-HD) Demonstrate Efficacy in Participants Without Antidopaminergic Medication
Session name - P6: Movement Disorders: Huntington's and Other Choreas 1; Program Number: P6.003. Presented by: Randal Hand, Director of Neuroscience, Prilenia Therapeutics; Tue, April 16, from 8:00-9:00a (MT)
Contacts
Prilenia
Communications Team
info@prilenia.com